Pharmaceutical Resource Technology IPO: revenue, profit and offering terms from its S-1
Pharmaceutical Resource Technology filed its S-1 on 11 Feb 2026, and has amended it 4 times. It has not set a price range yet. Revenue was $10.8 million in 2025, with a net profit of $264,820.
Headlines
- Revenue, 2025
- $11M
- Net income, 2025
- $264,820
- Price range
- Not set yet
Pharmaceutical Resource Technology IPO terms
From the newest registration statement. Terms left blank there are not set yet.
- Price range
- Not set yet
- Shares offered
- 100,000,000
- Expected to raise
- Not set yet
- Registered
- $135M, the amount the filing fee is paid on
- First filed
- 11 Feb 2026
Pharmaceutical Resource Technology revenue and profit
| Period | Revenue | Operating income | Net income |
|---|---|---|---|
| 2025 | $11M | - | $264,820 |
Pharmaceutical Resource Technology share structure and company facts
- Employees
- 2
- Headquarters
- Singapore
Pharmaceutical Resource Technology's IPO filings
The registration statement, each amendment and the final prospectus, oldest first.
About the data
- Terms and financials are read from Pharmaceutical Resource Technology's newest prospectus (S-1/A filed 9 Jun 2026) by a Kadoa workflow. Check figures that matter against the filing.
- Registered is the amount the filing fee is paid on, often a placeholder before the price range is set.
- Raised is the IPO price times the shares sold, without the underwriters' option. Trading compares the first and latest close with the IPO price.